A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
暂无分享,去创建一个
P. Cortesi | L. Mantovani | C. Fornari | P. Gisondi | E. Aloisi | M. Fiocchi | F. Iannone | I. Antonazzo | D. Ritrovato